Satellos Bioscience Inc (TSXV:MSCL)

Healthcare

Satellos Bioscience Inc is a Vancouver-based biotechnology company that focuses on reinventing and developing therapeutics treatment to restore degenerative muscle diseases.

The company operates MyoReGenX platform.

By using the technology, Satellos discover regeneration deficits in muscle diseases and provide treatments to correct the impaired muscle in regenerative process.

In partnership with Bloom Burton & Co, Frank Gleeson and Dr Michael Rudnicki incorporated the company in 2018.

Previously, the company was known as iCo Therapeutics Inc. In August 2021, the company underwent a reverse takeover transaction according to the Section 192 the Canada Business Corporations Act and changed its name to iCo Therapeutics Inc.

Satellos is a publicly listed company on the TSX Venture Exchange, and the common shares of the bio-technology company are traded under the ticker symbol ‘MSCL’.

MyoReGenX

The Rudnicki lab launched this technology that help in identify and develop therapeutic solutions to the impaired muscle. The company says that its technology is the first-in-class regenerative therapeutics solution that help to gain muscle strength, improve its quantity, quality and functioning.

It reformulates productive muscle’s and increase the life of Duchenne patients.

The technology helps aged person who lost the muscle strength, the firm claims. It restores the strength and regenerative deficit.

The Canadian firm provides solution to sarcopenia in which patient experience the loss in skeletal muscle mass and strength.

Oral-Trans™ Drug Formulation Technology

AmpB Technologies Inc developed Amp B technology that deliver non-water-soluble compounds orally. It is the subsidiary of Satellos that incorporates Oral-Trans, develops Amphotericin B and helps in providing treatment of systemic fungal and parasitic infections.

Oral Amphotericin B is used in various ways like preventing fungal infections in immunocompromised patients.

The Canadian company says that Amp B lowers the frequency of interaction and gives a possibility to develop drug resistance to fungal infections.

On August 25, 2021, the company developed a partnership with Jesse’s Journey to support Satellos in developing treatment for Duchenne patients.

Contact Information

company address 65 Front Street East, Suite 201 Toronto, Ontario M5E 1B5

company phone905 336-6128

company email[email protected]

company websitehttps://satellos.com/

Similar Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK